Associated Papers
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
Pisapia P et al.
Lung Cancer (amsterdam, Netherlands), 2024
Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma.
Salmani H et al.
Iranian Journal of Public Health, 2022
Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
Onozawa H et al.
Thoracic Cancer, 2020
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Wang Y et al.
Frontiers in Oncology, 2019
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q et al.
Molecular Medicine Reports, 2017
Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.
Asor E et al.
Plos One, 2017
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma.
Xu T et al.
Theranostics, 2017
Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.
Berois N et al.
Journal of Cancer Epidemiology, 2017
Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Mohar B et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2016
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH et al.
Expert Review of Molecular Diagnostics, 2016
Oligonucleotide gap-fill ligation for mutation detection and sequencing in situ.
Mignardi M et al.
Nucleic Acids Research, 2015
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
Wu Z et al.
Human Pathology, 2015
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
Paliogiannis P et al.
Molecular Medicine Reports, 2015
The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.
Xie G et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2015
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.
Wong SQ et al.
British Journal of Cancer, 2015
Determining lower limits of detection of digital PCR assays for cancer-related gene mutations.
Milbury CA et al.
Biomolecular Detection and Quantification, 2014
Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A et al.
Diagnostic Pathology, 2014
Highly sensitive EGFR mutation detection by specific amplification of mutant alleles.
Leelatian N et al.
Experimental and Molecular Pathology, 2014
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM et al.
Journal of Cancer Research and Clinical Oncology, 2013
Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM et al.
American Journal of Clinical Pathology, 2013
Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.
Akca H et al.
Cancer Genetics, 2013
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
Schuurbiers OC et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.
Lin CH et al.
Journal of Biomedical Science, 2010
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
Yung TK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T et al.
Bmc Cancer, 2008
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Gu D et al.
Human Mutation, 2007
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N et al.
Lung Cancer (amsterdam, Netherlands), 2007
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
Kang SM et al.
Cancer, 2007
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Sequist LV et al.
The Oncologist, 2007
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Yokoyama T et al.
Cancer Science, 2006
EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.
Sakaeda T et al.
Pharmaceutical Research, 2005
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma.
Sonobe M et al.
British Journal of Cancer, 2005
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Shigematsu H et al.
Journal of the National Cancer Institute, 2005